Injectables growth in North America falls short of expectations
- Hikma Pharmaceuticals upgrades guidance
- Injectables growth in North America lower than expected
- Short-term supply and capacity constraints affected growth
- Revenue growth and operating margins expected to be at lower end of guidance
- Branded division revenue growth guidance remains unchanged
- Generics revenue and operating margin guidance lowered
- Company on track to deliver strong earnings growth for the full year
Hikma Pharmaceuticals has announced an upgrade to its guidance, despite facing challenges in its injectables business in North America. The company reported that growth in this division has been lower than expected due to short-term supply and capacity constraints, which have now started to ease. As a result, Hikma expects its full-year revenue growth and operating margins to be at the lower end of its previous guidance. However, the company’s branded division revenue growth guidance remains unchanged, with expectations of mid-to-high single digits on a constant-currency basis. On the other hand, the generics division is expected to see lower revenue and operating margins compared to previous guidance. Despite these challenges, Hikma remains confident in its ability to deliver strong earnings growth for the full year.
Factuality Level: 7
Factuality Justification: The article provides information about Hikma Pharmaceuticals stating that growth in its injectables business in North America has been lower than expected and that revenue growth and operating margins are expected to be at the lower end of guidance. It also mentions that the growth has been affected by short-term supply and capacity constraints, which have started easing. The article includes specific figures and previous guidance for revenue growth and operating margins. However, it does not provide any sources or additional context to verify the information.
Noise Level: 3
Noise Justification: The article provides clear information about Hikma Pharmaceuticals’ lower than expected growth in its injectables business in North America. It mentions the reasons for the lower growth and provides details about the company’s revenue growth and operating margins. The article also includes information about the company’s guidance and upgrades to its full-year guidance. Overall, the article stays on topic, provides relevant information, and supports its claims with specific details.
Financial Relevance: Yes
Financial Markets Impacted: The news article pertains to the pharmaceutical industry, specifically Hikma Pharmaceuticals. It mentions that growth in Hikma’s injectables business in North America has been lower than expected, which could impact the company’s revenue and operating margins.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article discusses the financial performance of Hikma Pharmaceuticals, indicating that their injectables business in North America has been affected by short-term supply and capacity constraints. While this may have an impact on the company’s revenue and operating margins, there is no mention of an extreme event or any specific rating of its impact.
Public Companies: Hikma Pharmaceuticals (Hikma)
Key People:
Reported publicly:
www.marketwatch.com 
